百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Submitted by cheukllui3 on
Anti-Cancer
Chemical Biology
Chemistry
Novel tridimensional anticancer agents developed to fight against drug-resistant cancer cells

A research team co-led by chemists from City University of Hong Kong (CityU) recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells. The findings help provide a new direction for anticancer drug development.

Cancer has long been a devastating disease, which affects millions of people worldwide. Despite advances in treatment, current anticancer drugs often have limited effectiveness, lack of cancer selectivity, serious side effects and drug resistance in cancer cells.

“The structure of drugs greatly affects their anticancer performance,” explained Dr. Guangyu Zhu in the Department of Chemistry at CityU. “Most anticancer drugs have planar structures; developing new compounds with tridimensional structures may provide an opportunity to address the limitations of current anticancer drugs.”

In collaboration with researchers from The Hong Kong University of Science and Technology (HKUST), the team tested a new class of tridimensional and chiral compounds, which exhibit promising anticancer activity and present action mechanisms that are distinct from conventional anticancer drugs to overcome drug resistance.

anticancer agents
The half maximal inhibitory concentration (IC50 value) of synthetic lead compounds and clinical drug doxorubicin (DOX) in lung cancer stem cells and normal cells after incubation for 72 hours. Credit: Dr. Guangyu Zhu’s Research Group / City University of Hong Kong

The team first developed a new, highly efficient catalytic synthetic strategy to obtain a novel class of tridimensional and chiral tetraarylmethane compounds that presented better anticancer activity and lower toxicity than the clinical anticancer drug doxorubicin.

In their experiments, the research team tested the compounds with cancer cells in vitro, using doxorubicin as a control. They found that the tetraarylmethane compounds were more cytotoxic to cancer cells, including lung cancer stem cells (LCSCs), which are notorious for their drug resistance to clinical chemotherapeutic drugs, causing treatment failure. The compound also exhibited better cancer cell selectivity as it caused less harm to normal living cells, suggesting lower toxicity.

anticancer agents
SAR analysis of the synthetic compounds. The key factors that
contribute to the anticancer activity of this type of compound are indicated. The presence of certain substituents, including halogen and hydroxyl groups, at certain positions in the tetraarylmethane compounds significantly improves cytotoxicity. TMS, trimethylsilyl; Me, methyl. Credit: ? Tan, X. et al.: https://www.nature.com/articles/s44160-022-00211-4

The team further analyzed the structure-activity relationship of synthesized compounds. They found that the presence of certain substituents, including halogen and hydroxyl groups, at certain positions of the tetraarylmethane compounds significantly improved their cytotoxicity to cancer cells. Upon treatment with the synthesized compound, some cancer cells started to die, as organelle swelling, cell membrane permeabilization, nuclear shrinkage and fragmentation were observed. This suggests that necrotic cell death might have been triggered by the tetraarylmethane compounds.

In the fight against cancer, the majority of anticancer drugs currently available rely on the activation of apoptotic pathways to eliminate cancer cells. However, a promising new avenue of research for reducing drug resistance lies in the development of novel anticancer agents that target alternative cell death pathways. In their experiments, the team found that these innovative compounds induced a different cell death pathway. This suggests that the compounds can bypass the resistance mechanisms generated by conventional drugs, making them highly desirable for further exploration in the field of cancer treatment.

“The satisfactory anticancer performance and unique mechanism make these compounds potential candidates for anticancer agents for further development,” said Dr. Zhu. The team plans to synthesize more compounds and conduct further experiments to evaluate their anticancer performance.

anticancer agents
The synthesised lead compounds induced necroptosis in lung cancer stem cells. The arrows indicate cell membrane permeabilization. Credit: ? Tan, X. et al. https://www.nature.com/articles/s44160-022-00211-4

Their findings were published in the scientific journal Nature Synthesis under the title "Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution".

The corresponding authors are Dr. Zhu and Professor Jianwei Sun from HKUST. The co-first authors are Dr. Xuefeng Tan from HKUST and Dr. Zhiqin Deng, former postdoc in Dr Zhu’s research group at CityU.

The research received financial support from the National Natural Science Foundation of China, the Science, Technology and Innovation Committee of Shenzhen Municipality, the Hong Kong Research Grants Council, and the Innovation and Technology Commission.

 

This research article originated from CityU Research Stories.

百家乐总厂在哪里| 优博百家乐官网娱乐城| 金彩百家乐官网的玩法技巧和规则 | 百家乐免费破解外挂| 娱乐城大全| 做生意门口朝向| 百利宫娱乐城官方网| 做生意的好风水| 线上娱乐城| 百家乐游戏大厅下| 大发百家乐官网游戏| 速博百家乐的玩法技巧和规则| 百家乐官网平投注法| 威尼斯人娱乐城博彩网站| 金木棉百家乐官网的玩法技巧和规则 | 百家乐官网投注翻倍方法| 手机百家乐能兑换现金棋牌游戏| 视频百家乐官网代理| 棋牌新教室| BB百家乐大转轮| 百家乐官网大老娱乐| 长沙百家乐的玩法技巧和规则| 百家乐官网赌场赌场平台| 百家乐官网单机破解版| game88city| 百家乐必赢法冯耘| 百家乐官网赢钱lv| 威尼斯人娱乐场官网网站是多少| 百家乐官网群详解包杀| 百家乐官网现金网排名| 大发888网页版登陆| 百家乐三号的赢法| 百家乐官网赌博公司| 芒康县| 德州扑克刷分| 百家乐平台送彩金| 百家乐官网平注法到| 云鼎百家乐官网程序开发有限公司| 利博国际娱乐| 二八杠麻将做记号| 自贡百家乐赌场娱乐网规则|